User banner image
User avatar
  • admin

Posts

Carolina Dybeck Happe resigns from Ericsson’s Board of Directors

STOCKHOLM, Sept. 21, 2024 /PRNewswire/ — Ericsson (NASDAQ: ERIC) today announces that Carolina Dybeck Happe has decided to resign from its Board of Directors. Dybeck...

PRADA SPRING/SUMMER 2025 WOMENSWEAR SHOW

Beauty looks created by Lynsey Alexander, Global Creative Makeup Artist of Prada Beauty MILAN, Sept. 21, 2024 /PRNewswire/ — The Prada Spring/Summer 2025 Womenswear fashion show was...

Fosi Audio Launches 7th Anniversary Celebration with the Theme “Your Voice Rocks & Sparks”

NEW YORK, Sept. 20, 2024 /PRNewswire/ — Fosi Audio, a beloved brand among audiophiles worldwide, has officially launched its grand 7th-anniversary celebration under the theme “Your...

Open letter from the Chief Executive Officer.

HOLLYWOOD, FL, Sept. 20, 2024 (GLOBE NEWSWIRE) — Healthy Choice Wellness Corp. (“HCWC” or the “Company”) (NYSEAM: HCWC), a holding company focused on providing consumers...

UAE Cosmetic Pigments Market Trends, Competitive Landscape, Forecast and Opportunities, 2024-2029

Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) — The “UAE Cosmetic Pigments Market, By Region, Competition, Forecast and Opportunities, 2019-2029F” report has been added to ResearchAndMarkets.com’s...

Honey Powder Market Report 2024-2030: Organic, Conventional, Food & Beverages, Beauty, Personal Care Size, Share & Trends Analysis

Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) — The “Honey Powder Market Size, Share & Trends Analysis Report By Type (Organic, Conventional), By Application (Food &...

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™

OPUVIZ™, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency...

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements...

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase...

DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma

Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting Findings showed 60 percent reduction in risk...